Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2022-07-29 Legal Proceedings Report
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(제3상 가교 임상시험계획(IND) 신청)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure from HLB Life Science regarding the filing of a Phase 3 clinical trial application (IND) with the Ministry of Food and Drug Safety (MFDS). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market, which is used to announce significant corporate developments such as clinical trial progress. Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a formal regulatory announcement of a material event, it is classified as a Regulatory Filing (RNS).
2022-07-29 Korean
주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission and the Korea Exchange. It details a corporate merger (회사합병 결정) between HLB Life Science and its subsidiary AIM Co., Ltd. This type of regulatory filing regarding M&A activity is classified under the 'M&A Activity' category.
2022-07-18 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the setting of a record date and shareholder register closure for a small-scale merger. It does not contain the full merger agreement or financial statements, but rather serves as a formal regulatory announcement of a corporate action. As it does not fit into specific categories like M&A (TAR) or Dividend (DIV), and is a standard regulatory disclosure, it is classified as a general regulatory filing.
2022-07-18 Korean
회사합병결정(종속회사의주요경영사항)
M&A Activity Classification · 100% confidence The document is an official regulatory filing regarding a corporate merger ('회사합병 결정') between HLB Life Science and its subsidiary, Aim Co., Ltd. It details the merger method, purpose, ratio, and schedule. This falls under M&A activity, which is categorized as 'TAR'.
2022-07-18 Korean
회사합병결정(종속회사의주요경영사항)
M&A Activity Classification · 100% confidence The document is a formal regulatory filing regarding a corporate merger ('회사합병 결정') between a subsidiary (HLB Cell) and another entity (Aimtech). It details the merger method, purpose, ratios, and schedule. This falls under the category of M&A activity (Mergers and Acquisitions).
2022-07-18 Korean
증권발행결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) filing from HLB Life Science. It details the finalization of a private placement of convertible bonds (45 billion KRW). This falls under financing activities and capital structure changes, which aligns with the 'Capital/Financing Update' category.
2022-07-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.